Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.
Piramal Imaging is honoured to announce it will provide funding and support, along with other industry partners, for a major clinical study titled, "Imaging Dementia – Evidence for Amyloid Scanning" (IDEAS). The trial is designed to evaluate the impact of positron emission tomography (PET) scanning of beta-amyloid deposits in the diagnosis of Alzheimer’s disease (AD) and Dementia in a defined patient population.

